The Burden of Tardive Dyskinesia in Patients with Mental Disorders
https://doi.org/10.31363/2313-7053-2025-4-1261
Abstract
Tardive tardive dyskinesia (TD) is a serious, often disabling movement disorder caused by dopamine receptor blocking drugs, including antipsychotics. TD is quite common, but controlling risk factors can, in theory, reduce the likelihood of iatrogenic development. TD has a colossal negative impact on all areas of a patient's life, including physical and psychological well-being, social satisfaction, and the course of the underlying mental illness. Currently, there is no standard treatment approach. However, specialists have treatment options that can significantly alleviate the condition. One such drug is amantadine sulfate (PК-Merz), which has demonstrated sufficient efficacy and safety in this patient population.
About the Authors
D. V. Zakharov
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
Denis V. Zakharov
St. Petersburg
N. G. Neznanov
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
Nikolay G. Neznanov
St. Petersburg
References
1. Vayman EE, Shnayder NA, Neznanov NG, et al. Pathophysiological mechanisms underlying antipsychotic-induced tardive dyskinesia. Byulleten' sibirskoj mediciny. 2019;18(4):169-184. (In Russ.). https://doi.org/10.20538/1682-0363-2019-4-169-184
2. Zakharov DV, Buryak YuV, Mikhailov VA. Tardive (Late) Neuroleptic-Induced Dyskinesias. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2022;122(1):31–35. (In Russ.). https://doi.org/10.17116/jnevro202212201131
3. Khublarova LA, Zakharov DV, Mikhaylov VA. Stratification of the risk of developing tardive drug-induced complications. Obozrenie psihiatrii i medicinskoj psihologii imeni V.M. Bekhtereva. 2017;(4):111-114. (In Russ.).
4. Hublarova LA, Zakharov DV, Mikhailov VA, et al. Dynamics of the quality of life of patients with tardive form of neuroleptic dyskinesia during botulinum therapy. Obozrenie psihiatrii i medicinskoj psihologii imeni V.M. Bekhtereva. 2016;(4):86-91. (In Russ.).
5. Ayyagari R, Goldschmidt D, Mu F, et al. An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia. Clin Psychopharmacol Neurosci. 2022;20(1):154-166. https://doi.org/10.9758/cpn.2022.20.1.154
6. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry. 2008;13(5):544-56. https://doi.org/10.1038/sj.mp.4002142
7. Barer Y, Ribalov R, Yaari A, et al. The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis. J Clin Psychopharmacol. 2022;42(5):454-460. https://doi.org/10.1097/JCP.0000000000001597
8. Ben-Shlomo Y, Camfield L, Warner T; ESDE collaborative group. What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry. 2002;72(5):608-14. https://doi.org/10.1136/jnnp.72.5.608
9. Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J. 2011;87(1024):132-41. https://doi.org/10.1136/pgmj.2010.103234
10. Burke RE, Fahn S, Jankovic J et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32(12):1335-46. https://doi.org/10.1212/wnl.32.12.1335
11. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J Clin Psychiatry. 2017;78(3):e264-e278. https://doi.org/10.4088/JCP.16r10832.
12. Caroff SN. Recent Advances in the Pharmacology of Tardive Dyskinesia. Clin Psychopharmacol Neurosci. 2020;18(4):493-506. https://doi.org/10.9758/cpn.2020.18.4.493
13. Caroff SN, Jain R, Morley JF. Revisiting amantadine as a treatment for drug-induced movement disorders. Ann Clin Psychiatry. 2020;32(3):198-208
14. Carroll B, Irwin DE. Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia. J Manag Care Spec Pharm. 2019;25(7):810-816. https://doi.org/10.18553/jmcp.2019.25.7.810
15. Cho CH, Lee HJ. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:207-13. https://doi.org/10.1016/j.pnpbp.2012.10.018
16. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166-76. https://doi.org/10.1007/s13311-013-0222-5
17. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-25. https://doi.org/10.1176/appi.ajp.161.3.414
18. Correll CU, Kane JM, Citrome LL. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. J Clin Psychiatry. 2017;78(8):1136-1147. https://doi.org/10.4088/JCP.tv17016ah4c
19. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev. 2003;2003(2):CD003467. https://doi.org/10.1002/14651858.CD003467
20. Del Dotto P, Pavese N, Gambaccini G. et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord. 2001;16(3):515-20. https://doi.org/10.1002/mds.1112
21. Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord. 2010;16(7):438-41. https://doi.org/10.1016/j.parkreldis.2010.04.007
22. Faurbye Aб et al. Neurological symptoms in pharmagotherapy of psychoses. Acta Psychiatrica Scandinavica. 1964;40(1):10-27. https://doi.org/10.1111/j.1600-0447.1964.tb05731.x
23. Freedman DX. Neurological Syndromes Associated with Antipsychotic Drug Use: A Special Report. Arch Gen Psychiatry. 1973;28(4):463–467. https://doi.org/10.1001/archpsyc.1973.01750340009001
24. Frei K, Scott A, Caroff SN, Jankovic J, et al. Tardive dyskinesia versus tardive syndrome. What is in a name? Parkinsonism Relat Disord. 2025;133:107295. https://doi.org/10.1016/j.parkreldis.2025.107295
25. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry. 1993;54(4):133-9.
26. Haberfellner EM, Rittmannsberger H. Patientenwissen über tardive Dyskinesien [Patient knowledge regarding tardive dyskinesia]. Nervenarzt. 2006;77(3):333-7. German. https://doi.org/10.1007/s00115-005-1897-6
27. Jain G. Rapid response of disabling tardive dyskinesia to amantadine: a case report. Prim Care Companion CNS Disord. 2011;13(3):PCC.10l01098. https://doi.org/10.4088/PCC.10l01098
28. Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S. Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States. J Patient Rep Outcomes. 2023;7(1):122. https://doi.org/10.1186/s41687-023-00658-9
29. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39(4):473-81. https://doi.org/10.1001/archpsyc.1982.04290040069010
30. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503-10. https://doi.org/10.1192/bjp.158.4.503
31. Lieberman JA, Stroup TS, McEvoy JP et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23. https://doi.org/10.1056/NEJMoa051688
32. Mahmoudi S, Lévesque D, Blanchet PJ. Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. Mov Disord. 2014 Aug;29(9):1125-33. https://doi.org/10.1002/mds.25909
33. McEvoy JP. Psychosocial Implications of Tardive Dyskinesia in Patients With Mood Disorders Versus Schizophrenia. J Clin Psychiatry. 2019;80(6):NU18041BR2C. https://doi.org/10.4088/JCP.NU18041BR2C
34. Moraru E, Schnider P, Wimmer A et al. Relation between depression and anxiety in dystonic patients: implications for clinical management. Depress Anxiety. 2002;16(3):100-3. https://doi.org/10.1002/da.1003
35. Müller J, et al. Social anxiety and avoidance in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002;72:500–505.
36. Neznanov N, Vasilyeva A. Psychodynamic aspects of self-stigamtization. European Psychiatry. 2011;72:123–129. https://doi.org/10.1016/S0924-9338(12)75097-6
37. Niemann N, Jankovic J. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs. 2018;78(5):525-541. https://doi.org/10.1007/s40265-018-0874-x
38. Paracka L, Wegner F, Escher C, Klietz M, de Zwaan M, Abdallat M, Saryyeva A, Krauss JK. Body Concept and Quality of Life in Patients with Idiopathic Dystonia. Brain Sci. 2020;10(8):488. https://doi.org/10.3390/brainsci10080488
39. Pardis P, Remington G, Panda R, Lemez M, Agid O. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review. J Psychopharmacol. 2019;33(10):1187-1198. https://doi.org/10.1177/0269881119862535
40. Ray S, Pal PK, Yadav R. Non-Motor Symptoms in Cervical Dystonia: A Review. Ann Indian Acad Neurol. 2020;23(4):449-457. https://doi.org/10.4103/aian.AIAN_27_20
41. Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment Recommendations for Tardive Dyskinesia. Can J Psychiatry. 2019;64(6):388-399. https://doi.org/10.1177/0706743719828968
42. Rinnerthaler M, Mueller J, Weichbold V, Wenning GK, Poewe W. Social stigmatization in patients with cranial and cervical dystonia. Mov Disord. 2006;21(10):1636-40. https://doi.org/10.1002/mds.21049
43. Sakata M, Ito H. Late-Onset Dyskinesia Occurring During Antipsychotic Treatment for Schizophrenia: Management of Tardive Dyskinesia Based on the Latest Knowledge. Brain Nerve. 2022;74(5):571-574. https://doi.org/10.11477/mf.1416202082
44. Sandyk R, Kay SR. Suicidal behavior and tardive dyskinesia. Int J Neurosci. 1991;57(3-4):269-71. https://doi.org/10.3109/00207459109150701
45. Schonecker M. Paroxysmale Dyskinesen als Megaphenwirung [ Paroxysmal dyskinesia as the effect of megaphen]. Nervenarzt. 1957;28(12):550-3
46. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27(2):159-69. https://doi.org/10.1055/s-2007-971169
47. Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: A clinical comparison. J Neurol Neurosurg Psychiatry. 2000;68(2):186–90. https://doi.org/10.1136/jnnp.68.2.186
48. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol. 2011;100:601-16. https://doi.org/10.1016/B978-0-444-52014-2.00043-4
49. Tenback DE, van Harten PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol. 2011;98:211-30. https://doi.org/10.1016/B978-0-12-381328-2.00009-2.
50. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012;27(10):1205-15. https://doi.org/10.1002/mds.25107
51. Torres JAKL, Rosales RL. Nonmotor Symptoms in Dystonia. Int Rev Neurobiol. 2017;134:1335-1371. https://doi.org/10.1016/bs.irn.2017.05.003
52. Vasan S., Padhy R.K. Tardive Dyskinesia. In StatPearls Publishing; 2025.
53. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18(4):701-15. https://doi.org/10.1093/schbul/18.4.701
54. Zurowski M, McDonald WM, Fox S, Marsh L. Psychiatric comorbidities in dystonia: emerging concepts. Mov Disord. 2013;28(7):914-20. https://doi.org/10.1002/mds.25501
Review
For citations:
Zakharov D.V., Neznanov N.G. The Burden of Tardive Dyskinesia in Patients with Mental Disorders. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2025;59(4):18-24. (In Russ.) https://doi.org/10.31363/2313-7053-2025-4-1261
Views:
424
JATS XML
Email this article 